Investing.com - Canaccord Genuity周五将 DexCom (NASDAQ:DXCM) 的目标价从99.00美元下调至95.00美元，同时维持对这家连续血糖监测公司的买入评级。根据 InvestingPro 数据，DexCom目前交易价格低于其公允价值，分析师共识推荐评级强劲，为1.48（其中1表示强烈买入）。
Dexcom Inc.（纳斯达克股票代码：DXCM）于2026年2月12日发布了2025年第四季度财报演示，尽管连续血糖监测（CGM）市场面临挑战，公司仍展现出强劲的财务表现。尽管超出分析师预期，该公司股价在盘后交易中下跌4.45%至68.15美元，这表明投资者可能预期更强劲的业绩或指引。 公司继续在竞争激烈的CGM市场中前进，同时通过创新产品扩大其产品组合，旨在拓宽其可服务市场。Dexcom对国 ...
Deep-pocketed investors have adopted a bearish approach towards DexCom (NASDAQ:DXCM), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled ...
DexCom's growth rate has been accelerating for multiple quarters, and recently came in at around 22%. A rise in GLP-1 drugs has some investors concerned that DexCom's growth opportunities may be ...
Shares of medical device company DexCom (NASDAQ:DXCM) jumped 7.3% in the morning session after it reported better-than-expected fourth-quarter 2025 financial results, beating analyst estimates for ...
SAN DIEGO--(BUSINESS WIRE)-- DexCom, Inc. (DXCM) (NASDAQ:DXCM), the global leader in glucose biosensing, announced today the FDA has cleared the Dexcom G7 15 Day Continuous Glucose Monitoring System ...
Add Yahoo as a preferred source to see more of our stories on Google. (COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in ...
(COLORADO SPRINGS) — A medical device for diabetes called the Dexcom is facing a national shortage that’s now leaving diabetics in Southern Colorado frustrated. A Dexcom is responsible for monitoring ...
Medical Device Network on MSN
Dexcom reports 2025 revenues of $4.66bn yet 2026 outlook lags analyst expectations
Dexcom's 2026 revenue estimates lagged analysts' expectations, according to data compiled by the London Stock Exchange Group ...
Q4 2025 Earnings Call February 12, 2026 4:30 PM ESTCompany ParticipantsSean Christensen - Vice President of Finance and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果